PT4069231T - Combinações de masupirdina com donepezilo ou memantina para tratamento de sintomas comportamentais e psicológicos em pacientes com demência - Google Patents

Combinações de masupirdina com donepezilo ou memantina para tratamento de sintomas comportamentais e psicológicos em pacientes com demência

Info

Publication number
PT4069231T
PT4069231T PT208286740T PT20828674T PT4069231T PT 4069231 T PT4069231 T PT 4069231T PT 208286740 T PT208286740 T PT 208286740T PT 20828674 T PT20828674 T PT 20828674T PT 4069231 T PT4069231 T PT 4069231T
Authority
PT
Portugal
Prior art keywords
dementia
patients
methods
psychological symptoms
treating behavioral
Prior art date
Application number
PT208286740T
Other languages
English (en)
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of PT4069231T publication Critical patent/PT4069231T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
PT208286740T 2019-12-02 2020-12-02 Combinações de masupirdina com donepezilo ou memantina para tratamento de sintomas comportamentais e psicológicos em pacientes com demência PT4069231T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941049515 2019-12-02
IN201941049513 2019-12-02

Publications (1)

Publication Number Publication Date
PT4069231T true PT4069231T (pt) 2025-08-01

Family

ID=73857227

Family Applications (1)

Application Number Title Priority Date Filing Date
PT208286740T PT4069231T (pt) 2019-12-02 2020-12-02 Combinações de masupirdina com donepezilo ou memantina para tratamento de sintomas comportamentais e psicológicos em pacientes com demência

Country Status (24)

Country Link
US (1) US20230000859A1 (pt)
EP (1) EP4069231B1 (pt)
JP (2) JP2023510082A (pt)
KR (1) KR20220110518A (pt)
CN (1) CN114761008B (pt)
AU (1) AU2020396396A1 (pt)
BR (1) BR112022010540A2 (pt)
DK (1) DK4069231T3 (pt)
ES (1) ES3036880T3 (pt)
FI (1) FI4069231T3 (pt)
HR (1) HRP20250882T1 (pt)
HU (1) HUE073179T2 (pt)
IL (1) IL293373A (pt)
LT (1) LT4069231T (pt)
MA (1) MA57828B1 (pt)
MD (1) MD4069231T2 (pt)
MX (1) MX2022006537A (pt)
PL (1) PL4069231T3 (pt)
PT (1) PT4069231T (pt)
RS (1) RS67022B1 (pt)
SI (1) SI4069231T1 (pt)
SM (1) SMT202500286T1 (pt)
WO (1) WO2021111320A1 (pt)
ZA (1) ZA202205914B (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4559230B2 (ja) 2002-11-28 2010-10-06 スベン ライフ サイエンシズ リミティド セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
KR20140041670A (ko) * 2011-06-03 2014-04-04 엘란 파마슈티컬스, 엘엘씨 행동 장애 및 정신 장애의 치료를 위한 실로―이노시톨
HUE036008T2 (hu) 2013-12-02 2018-06-28 Suven Life Sciences Ltd Eljárás 1-[(2-brómfenil)szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol-dimezilát-monohidrát nagyüzemi léptékben történõ elõállítására
US10864191B2 (en) 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
EP3458040B1 (en) * 2016-05-18 2021-01-27 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
DK3458039T3 (da) * 2016-05-18 2020-09-14 Suven Life Sciences Ltd Tripelkombination af rene 5-ht6-receptorantagonister, acetylcholinesterasehæmmere og nmda-receptorantagonist
EA036347B1 (ru) 2016-05-18 2020-10-29 Сувен Лайф Сайенсиз Лимитед Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы
CN110799189A (zh) 2017-07-03 2020-02-14 苏文生命科学有限公司 纯5-ht6受体拮抗剂的新用途

Also Published As

Publication number Publication date
BR112022010540A2 (pt) 2022-08-16
US20230000859A1 (en) 2023-01-05
NZ788970A (en) 2025-05-02
CN114761008B (zh) 2024-07-19
AU2020396396A1 (en) 2022-06-16
KR20220110518A (ko) 2022-08-08
WO2021111320A1 (en) 2021-06-10
PL4069231T3 (pl) 2025-09-08
LT4069231T (lt) 2025-09-10
DK4069231T3 (da) 2025-08-18
ES3036880T3 (en) 2025-09-25
EP4069231B1 (en) 2025-07-09
EP4069231A1 (en) 2022-10-12
RS67022B1 (sr) 2025-08-29
HUE073179T2 (hu) 2026-01-28
JP2023510082A (ja) 2023-03-13
MA57828B1 (fr) 2025-09-30
MX2022006537A (es) 2022-12-13
CA3162938A1 (en) 2021-06-10
SI4069231T1 (sl) 2025-10-30
IL293373A (en) 2022-07-01
HRP20250882T1 (hr) 2025-09-26
ZA202205914B (en) 2024-10-30
MD4069231T2 (ro) 2025-10-31
JP2024156953A (ja) 2024-11-06
FI4069231T3 (fi) 2025-08-15
SMT202500286T1 (it) 2025-09-12
CN114761008A (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
IL290455A (en) Methods of treating psychological and brain disorders
SG11202012903TA (en) Methods and devices for reducing myopia in children
EP3801744A4 (en) METHOD AND DEVICE FOR TREATING SLEEP-RELATED RESPIRATORY DISORDERS
SI4014976T1 (sl) Aprocitentan za uporabo pri zdravljenju hipertenzije in sorodnih bolezni v kombinaciji z valsartanom
IL276247A (en) Methods and materials for the treatment of sleep apnea
PL3043862T3 (pl) Sposób weryfikacji i zapewnienia jakości leczenia radioterapeutycznego specyficznego dla pacjenta
LT3903795T (lt) Nervinio audinio vienetas ir tokio vieneto naudojimas implantuojant į žinduolio nervų sistemą
EP3826684A4 (en) METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
SG10202011470UA (en) Compositions and methods for treating negative symptoms in non-schizophrenic patients
GB2583322B (en) Method for managing behavioral treatment therapy and devices thereof
SG11202009953XA (en) Method for attaching bedpan diaper and bedpan with diaper
SG11202107842QA (en) Methods for treating symptoms and disorders associated with lysosomal storage diseases
GB201706747D0 (en) Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients
IL282965A (en) Electronic devices and treatment methods using antipsychotic drugs in combination with digital therapies
PT4069231T (pt) Combinações de masupirdina com donepezilo ou memantina para tratamento de sintomas comportamentais e psicológicos em pacientes com demência
PT4069232T (pt) Masupirdina para tratar sintomas comportamentais e psicológicos na demência
IL267534A (en) Low dose drug combinations for use in preventing and treating neuronal damage
WO2014135878A3 (en) Methods for treating cells with immunosuppressants to enhance their immunosuppressive potency
SG10202005848TA (en) Method for automatically validating cots and device for implementing the method
HK40050297A (en) Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
HK40039970A (en) Method and device for treating sleep related breathing disorders
GB2604524B (en) Patient turning apparatus and method
GB201706722D0 (en) Diagnostic methods and treatment in equine disease
GB201521358D0 (en) A method for the treatment and/or reduction of inflammation in a subject and diagnostic method thereof